Davis Polk Advises Freeline Therapeutics Holdings plc on Its $158.8 Million Initial Public Offering

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which included an upsize of 1,470,588 ADSs at the time of pricing. The ADSs are listed on the Nasdaq Global Select Market under the symbol “FRLN.”

Based in Stevenage, United Kingdom, Freeline Therapeutics is a clinical-stage, fully integrated, next generation, systemic adeno-associated virus-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. Freeline’s pipeline includes two programs in the clinic and two late-stage preclinical product candidates, as well as research programs targeting novel applications for systemic gene therapy.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Marcel Fausten and associates Joseph S. Payne and Eryn E. Gordon. Partner Simon Witty and counsel Simon J. Little provided English law advice. The executive compensation team included partner Kyoko Takahashi Lin. Partners Michael Mollerus and Jonathan Cooklin provided U.S. and English tax advice. Partner David R. Bauer and counsel Bonnie Chen provided intellectual property advice. Members of the Davis Polk team are based in the New York and London offices.